The finding that MK3-overexpression apparently reactivates dormant checkpoints in cancer cells is an important observation, as it holds the promise of identification of novel therapeutic targets and stresses the relevance of personalized anti-cancer approaches. The gene discussed is MAPKAPK3; the disease is cancer.